| 5FV1: reference: Novel interaction mechanism of a domain antibody based inhibitor of human vascular endothelial growth factor with greater potency than ranibizumab and bevacizumab and improved capacity over aflibercept., Walker A, Chung CW, Neu M, Burman M, Batuwangala T, Jones G, Tang CM, Steward M, Mullin M, Tournier N, Lewis A, Korczynska J, Chung V, Catchpole I, J Biol Chem. 2016 Jan 4. pii: jbc.M115.691162. PMID: 26728464 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).